Enhanced expression of retinoic acid receptor alpha (RARA) induces epithelial-to-mesenchymal transition and disruption of mammary acinar structures

Molecular Oncology

Volumn 9, Issue 2, 2015, Pages 355-364

  Doi, Ayano ^a   Ishikawa, Kosuke ^a,b   Shibata, Nao ^a   Ito, Emi ^c   Fujimoto, Jiro ^a,b   Yamamoto, Mizuki ^a   Shiga, Hatsuki ^b   Mochizuki, Hiromi ^b   Kawamura, Yoshifumi ^b   Goshima, Naoki ^d   Semba, Kentaro ^a,c   Watanabe, Shinya ^c  

^a WASEDA UNIVERSITY   (Japan)

^b Koto ku   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

3D culture; Breast cancer; EMT; ERBB2; Gene amplification; RARA

Indexed keywords

COLLAGEN TYPE 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; RETINOIC ACID RECEPTOR ALPHA; RNA; RNA 18S; SHORT HAIRPIN RNA; SMAD3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; RETINOIC ACID RECEPTOR; TUMOR PROTEIN;

ACINAR CELL; AMPLICON; ARTICLE; BREAST CANCER; BREAST CELL; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; MALIGNANT TRANSFORMATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION; UPREGULATION; BIOSYNTHESIS; BREAST TUMOR; CELL TRANSFORMATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MAMMARY GLAND; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY GLANDS, HUMAN; NEOPLASM PROTEINS; RECEPTORS, RETINOIC ACID;

EID: 84921323499     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.09.005     Document Type: Article

References (41)

1. Altucci L., Gronemeyer H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer 2001, 1:181-193.
2. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9:463-475.
3. Bastien J., Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 2004, 328:1-16.
4. Bieche I., Tomasetto C., Regnier C.H., Moog-Lutz C., Rio M.C., Lidereau R. Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer. Cancer Res. 1996, 56:3886-3890.
5. Burk U., Schubert J., Wellner U., Schmalhofer O., Vincan E., Spaderna S., Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9:582-589.
6. Chaffer C.L., Marjanovic N.D., Lee T., Bell G., Kleer C.G., Reinhardt F., D'Alessio A.C., Young R.A., Weinberg R.A. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013, 154:61-74.
7. Chiba H., Clifford J., Metzger D., Chambon P. Distinct retinoid X receptor-retinoic acid receptor heterodimers are differentially involved in the control of expression of retinoid target genes in F9 embryonal carcinoma cells. Mol. Cell. Biol. 1997, 17:3013-3020.
8. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162:156-159.
9. Cohn E., Ossowski L., Bertran S., Marzan C., Farias E.F. RARalpha1 control of mammary gland ductal morphogenesis and wnt1-tumorigenesis. Breast Cancer Res. 2010, 12:R79.
10. Debnath J., Brugge J.S. Modelling glandular epithelial cancers in three-dimensional cultures. Nat. Rev. Cancer 2005, 5:675-688.
11. Debnath J., Muthuswamy S.K., Brugge J.S. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268.
12. Espina V., Liotta L.A. What is the malignant nature of human ductal carcinoma in situ?. Nat. Rev. Cancer 2011, 11:68-75.
13. Farboud B., Hauksdottir H., Wu Y., Privalsky M.L. Isotype-restricted corepressor recruitment: a constitutively closed helix 12 conformation in retinoic acid receptors beta and gamma interferes with corepressor recruitment and prevents transcriptional repression. Mol. Cell. Biol. 2003, 23:2844-2858.
14. Gregory P.A., Bracken C.P., Smith E., Bert A.G., Wright J.A., Roslan S., Morris M., Wyatt L., Farshid G., Lim Y.Y., Lindeman G.J., Shannon M.F., Drew P.A., Khew-Goodall Y., Goodall G.J. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol. Biol. Cell 2011, 22:1686-1698.
15. Jacot W., Fiche M., Zaman K., Wolfer A., Lamy P.J. The HER2 amplicon in breast cancer: topoisomerase IIA and beyond. Biochim. Biophys. Acta 2013, 1836:146-157.
16. Kao J., Pollack J.R. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosomes Cancer 2006, 45:761-769.
17. Katz E., Dubois-Marshall S., Sims A.H., Faratian D., Li J., Smith E.S., Quinn J.A., Edward M., Meehan R.R., Evans E.E., Langdon S.P., Harrison D.J. A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. Br. J. Cancer 2010, 103:401-410.
18. Kauraniemi P., Barlund M., Monni O., Kallioniemi A. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res. 2001, 61:8235-8240.
19. Keith W.N., Douglas F., Wishart G.C., McCallum H.M., George W.D., Kaye S.B., Brown R. Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur. J. Cancer 1993, 29A:1469-1475.
20. Kleinman H.K., McGarvey M.L., Liotta L.A., Robey P.G., Tryggvason K., Martin G.R. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 1982, 21:6188-6193.
21. Lamy P.J., Fina F., Bascoul-Mollevi C., Laberenne A.C., Martin P.M., Ouafik L., Jacot W. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res. 2011, 13:R15.
22. Lu J., Guo H., Treekitkarnmongkol W., Li P., Zhang J., Shi B., Ling C., Zhou X., Chen T., Chiao P.J., Feng X., Seewaldt V.L., Muller W.J., Sahin A., Hung M.C., Yu D. 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 2009, 16:195-207.
23. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
24. Muthuswamy S.K., Li D., Lelievre S., Bissell M.J., Brugge J.S. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat. Cell Biol. 2001, 3:785-792.
25. Paroni G., Fratelli M., Gardini G., Bassano C., Flora M., Zanetti A., Guarnaccia V., Ubezio P., Centritto F., Terao M., Garattini E. Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA. Oncogene 2012, 31:3431-3443.
26. Peng X., Yun D., Christov K. Breast cancer progression in MCF10A series of cell lines is associated with alterations in retinoic acid and retinoid X receptors and with differential response to retinoids. Int. J. Oncol. 2004, 25:961-971.
27. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
28. Ross-Innes C.S., Stark R., Holmes K.A., Schmidt D., Spyrou C., Russell R., Massie C.E., Vowler S.L., Eldridge M., Carroll J.S. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev. 2010, 24:171-182.
29. Saito M., Kato Y., Ito E., Fujimoto J., Ishikawa K., Doi A., Kumazawa K., Matsui A., Takebe S., Ishida T., Azuma S., Mochizuki H., Kawamura Y., Yanagisawa Y., Honma R., Imai J., Ohbayashi H., Goshima N., Semba K., Watanabe S. Expression screening of 17q12-21 amplicon reveals GRB7 as an ERBB2-dependent oncogene. FEBS Lett. 2012, 586:1708-1714.
30. Schug T.T., Berry D.C., Shaw N.S., Travis S.N., Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 2007, 129:723-733.
31. Seton-Rogers S.E., Lu Y., Hines L.M., Koundinya M., LaBaer J., Muthuswamy S.K., Brugge J.S. Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc. Natl. Acad. Sci. U S A 2004, 101:1257-1262.
32. Stratton M.R., Campbell P.J., Futreal P.A. The cancer genome. Nature 2009, 458:719-724.
33. Taube J.H., Herschkowitz J.I., Komurov K., Zhou A.Y., Gupta S., Yang J., Hartwell K., Onder T.T., Gupta P.B., Evans K.W., Hollier B.G., Ram P.T., Lander E.S., Rosen J.M., Weinberg R.A., Mani S.A. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. U S A 2010, 107:15449-15454.
34. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
35. Toma S., Isnardi L., Raffo P., Riccardi L., Dastoli G., Apfel C., LeMotte P., Bollag W. RARalpha antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines. Int. J. Cancer 1998, 78:86-94.
36. Vargo-Gogola T., Rosen J.M. Modelling breast cancer: one size does not fit all. Nat. Rev. Cancer 2007, 7:659-672.
37. Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., Waldvogel B., Vannier C., Darling D., zur Hausen A., Brunton V.G., Morton J., Sansom O., Schuler J., Stemmler M.P., Herzberger C., Hopt U., Keck T., Brabletz S., Brabletz T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 2009, 11:1487-1495.
38. Witt A.E., Hines L.M., Collins N.L., Hu Y., Gunawardane R.N., Moreira D., Raphael J., Jepson D., Koundinya M., Rolfs A., Taron B., Isakoff S.J., Brugge J.S., LaBaer J. Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J.Proteome Res. 2006, 5:599-610.
39. Yamada K.M., Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130:601-610.
40. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 2008, 14:818-829.
41. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.